SEC22B

Across TCGA pan-cancer cohorts, SEC22B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SEC22B data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SEC22B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SEC22B expression acts as an unfavorable survival marker, although some lineages such as COAD and HNSC show a favorable association.

CCRCC, COAD, and HNSC are the cancer types where SEC22B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.525	1.000	.001	23	view →
COAD	DFS	Median	IV	1.000	0.605	.043	12	view →
HNSC	DFS	Median	All	0.748	0.540	.010	9	view →
LUAD	OS	Median	II,III,IV	0.493	0.792	.011	8	view →
UCEC	DFS	Median	All	0.789	0.944	.014	6	view →
PDAC	DFS	Quartile	III,IV	0.676	0.226	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SEC22B–CCRCC (OS)

Open the CCRCC breakdown →